Intravitreal Anti-vascular Endothelial Growth Factor for Treating Polypoidal Choroidal Vasculopathy with Grape-like Polyp Clusters
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate 12-month outcomes of anti-vascular endothelial growth factor (VEGF) therapy for polypoidalchoroidal vasculopathy (PCV) with grape-like polyp clusters. Methods: This retrospective observational study included 23 eyes of 23 patients who were newly diagnosedwith PCV with grape-like polyp clusters, and who were subsequently treated with anti-VEGF monotherapy. The study compares the best-corrected visual acuity (BCVA) of the patients at diagnosis, at 3 months, and at12 months after diagnosis. In addition, 12-month changes in BCVA values were compared between cases withsubfoveal or juxtafoveal polyps and cases with extrafoveal polyps. Results: The baseline, 3-month, and 12-month logarithm of the minimal angle of resolution BCVA was 0.62 ±0.35, 0.50 ± 0.43, and 0.58 ± 0.48, respectively. Compared to the baseline, patient BCVA was not significantlydifferent at 12 months after diagnosis (p = 0.764). Six eyes (26.1%) gained ≥0.2 logarithm of the minimal angleof resolution BCVA. In cases with subfoveal or juxtafoveal polyps, BCVA values at baseline and at 12 monthsafter diagnosis were 0.66 ± 0.37 and 0.69 ± 0.53, respectively. In cases with extrafoveal polyps, the valueswere 0.54 ± 0.33 and 0.37 ± 0.31, respectively. Changes in BCVA values were significantly different betweenthe two groups (p = 0.023). Conclusions: Although anti-VEGF therapy has favorable short-term efficacy for treating PCV with grape-likepolyp clusters, long-term visual improvements are generally limited in the majority of afflicted
Abstract
Purpose: To evaluate 12-month outcomes of anti-vascular endothelial growth factor (VEGF) therapy for polypoidalchoroidal vasculopathy (PCV) with grape-like polyp clusters. Methods: This retrospective observational study included 23 eyes of 23 patients who were newly diagnosedwith PCV with grape-like polyp clusters, and who were subsequently treated with anti-VEGF monotherapy. The study compares the best-corrected visual acuity (BCVA) of the patients at diagnosis, at 3 months, and at12 months after diagnosis. In addition, 12-month changes in BCVA values were compared between cases withsubfoveal or juxtafoveal polyps and cases with extrafoveal polyps. Results: The baseline, 3-month, and 12-month logarithm of the minimal angle of resolution BCVA was 0.62 ±0.35, 0.50 ± 0.43, and 0.58 ± 0.48, respectively. Compared to the baseline, patient BCVA was not significantlydifferent at 12 months after diagnosis (p = 0.764). Six eyes (26.1%) gained ≥0.2 logarithm of the minimal angleof resolution BCVA. In cases with subfoveal or juxtafoveal polyps, BCVA values at baseline and at 12 monthsafter diagnosis were 0.66 ± 0.37 and 0.69 ± 0.53, respectively. In cases with extrafoveal polyps, the valueswere 0.54 ± 0.33 and 0.37 ± 0.31, respectively. Changes in BCVA values were significantly different betweenthe two groups (p = 0.023). Conclusions: Although anti-VEGF therapy has favorable short-term efficacy for treating PCV with grape-likepolyp clusters, long-term visual improvements are generally limited in the majority of afflicted
참고문헌 (25)
- Oishi A, "Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results", Am J Ophthalmol, 156, pp.644~651 (2013)
- Cheng CK, "One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy", Retina, 31, pp.846~856 (2011)
- Hikichi T, "Results of 2years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy", Br J Ophthalmol, 97, pp.617~621 (2013)
- Sun Young Lee, "The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy", Korean Journal of Ophthalmology, 22(2), pp.92~99 (2008), 대한안과학회
- Chan WM, "Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy:one-year results of a prospective case series", Ophthalmology, 111, pp.1576~1584 (2004)
- Inoue M, "Longterm outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy", Eye (Lond), 27, pp.1013~1020 (2013)
- Tomita K, "Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab", Am J Ophthalmol, 153, pp.68~80 (2012)
- Lee JH, "Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters", Graefes Arch Clin Exp Ophthalmol, 254, pp.645~651 (2016)
- Lee WK, "Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters", Am J Ophthalmol, 154, pp.355~365 (2012)
- Sho K, "Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics", Arch Ophthalmol, 121, pp.1392~1396 (2003)
- Uyama M, "Polypoidal choroidal vasculopathy: natural history", Am J Ophthalmol, 133, pp.639~648 (2002)
- Lai TY, "Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy", Retina, 31, pp.1581~1588 (2011)
- Tsujikawa A, "Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab", Jpn J Ophthalmol, 54, pp.310~319 (2010)
- Wakabayashi T, "Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy", Br J Ophthalmol, 96, pp.394~399 (2012)
- Gemmy Cheung CM, "Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy", Am J Ophthalmol, 155, pp.295~304 (2013)
- Hou J, "Clinical characteristics of polypoidal choroidal vasculopathy in Chinese patients", Graefes Arch Clin Exp Ophthalmol, 249, pp.975~979 (2011)
- Parodi MB, "Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration", Retina, 34, pp.2167~2170 (2014)
- Saito M, "Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab", Retina, 34, pp.2192~2201 (2014)
- Yamashita M, "Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab", Clin Ophthalmol, 8, pp.343~346 (2014)
- Kang HM, "Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy", Am J Ophthalmol, 156, pp.652~660 (2013)
- Fung AE, "An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration", Am J Ophthalmol, 143, pp.566~583 (2007)
- Rauch R, "Time to first treatment: The significance of early treatment of exudative age-related macular degeneration", Retina, 32, pp.1260~1264 (2012)
- Arias L, "Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss", Eye (Lond), 23, pp.326~333 (2009)
- Koh A, "EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy", Retina, 32, pp.1453~1464 (2012)
- Koh AH, "Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment", Retina, 33, pp.686~716 (2013)